Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. Februar 2023 07:00 ET | Quelle: EuMentis Therapeutics, Inc.

EuMentis Therapeutics Inc. Announces the First Closing of a Targeted $40M Series B Financing to Advance Novel Therapeutics to Treat Autism Spectrum Disorder, Tourette Syndrome and Traumatic Brain Injury

EuMentis is developing novel therapeutics with clinically validated mechanisms for the treatment of neurodevelopmental and neuropsychiatric conditionsEuMentis plans to initiate Phase 2 clinical trials...
08. Februar 2023 07:00 ET | Quelle: EuMentis Therapeutics, Inc.

EuMentis Therapeutics Inc. Receives $3 Million Award from United States Department of Defense (DoD) to Advance its Novel NMDA Receptor Antagonist for Traumatic Brain Injury

Under the DoD award, EuMentis will conduct preclinical TBI studies in validated large animal model in collaboration with Dr. Todd Killbaugh at the Children’s Hospital of Philadelphia (CHOP) and plans...